{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:14:04Z","timestamp":1791684844029,"version":"4.3.4"},"reference-count":199,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In calendar year 2023, the United States Food and Drug Administration (US FDA) approved a total of 55 new molecular entities, of which 12 were in the class of therapeutic antibodies. Besides antibody protein drugs, the US FDA also approved another five non-antibody protein drugs, making the broader class of protein drugs about 31% of the total approved drugs. Among the 12 therapeutic antibodies approved by the US FDA, 8 were relatively standard IgG formats, 3 were bivalent, bispecific antibodies and 1 was a trivalent, bispecific antibody. In 2023, no new antibody\u2013drug conjugates, immunocytokines or chimeric antigen receptor-T cells were approved. Of the approved antibodies, two targeted programmed cell death receptor-1 (PD-1) for orphan indications, two targeted CD20 for diffuse large B cell lymphoma, two targeted different receptors (B-cell maturation antigen [BCMA] and G-coupled protein receptor class C, group 5, member D [GPRC5D]) for treatment of multiple myeloma, and one each that targeted amyloid-\u03b2 protofibrils for Alzheimer\u2019s disease, neonatal Fc receptor alpha-chain for myasthenia gravis, complement factor C5 for CD55 deficiency with hyper-activation of complement, angiopathic thrombosis and severe protein-losing enteropathy disease, interleukin (IL)-23p19 for severely active ulcerative colitis, IL-17A-F for plaque psoriasis and respiratory syncytial virus (RSV)-F protein for season-long RSV prophylaxis in infants.<\/jats:p>","DOI":"10.1093\/abt\/tbae007","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T19:08:31Z","timestamp":1710529711000},"page":"132-156","source":"Crossref","is-referenced-by-count":30,"title":["Structure and function of therapeutic antibodies approved by the US FDA in 2023"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6875","authenticated-orcid":false,"given":"William R","family":"Strohl","sequence":"first","affiliation":[{"name":"BiStro Biotechnology Consulting Scientific Advisor Department, , 1086 Tullo Farm Rd., Bridgewater, NJ 08807,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"2026050905165379200_ref1","volume-title":"U.S Food and Drug Administration","author":"Novel drug approvals for 2023"},{"key":"2026050905165379200_ref2","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"2026050905165379200_ref3","doi-asserted-by":"crossref","first-page":"2297450","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"MAbs"},{"key":"2026050905165379200_ref4","volume-title":"U.S Food and Drug Administration","author":"Approved cellular and gene therapy products"},{"key":"2026050905165379200_ref5","volume-title":"WHO Drug Info","author":"Lecanemabum"},{"key":"2026050905165379200_ref6","author":"Leqembi\u00ae Prescribing information","year":"2023"},{"key":"2026050905165379200_ref7","first-page":"83","volume-title":"WHO Drug Info","author":"Retifanlimabum"},{"key":"2026050905165379200_ref8","author":"Zynyz\u00ae Prescribing information","year":"2023"},{"key":"2026050905165379200_ref9","first-page":"31","volume-title":"WHO Drug Info","author":"Epcoritamabum"},{"key":"2026050905165379200_ref10","author":"Epkily\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref11","volume-title":"WHO Drug Info","author":"Glofitamabum"},{"key":"2026050905165379200_ref12","author":"Columvi\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref13","first-page":"125","volume-title":"WHO Drug Info","author":"Rozanolixizumabum"},{"key":"2026050905165379200_ref14","author":"Rystiggo\u00ae Prescribing information","year":"2023"},{"key":"2026050905165379200_ref15","volume-title":"WHO Drug Info","author":"Nirsevimabum"},{"key":"2026050905165379200_ref16","author":"Beyfortus\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref17","volume-title":"WHO Drug Info","author":"Talquetamabum"},{"key":"2026050905165379200_ref18","author":"Talvey\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref19","volume-title":"WHO Drug Info","author":"Elranatamabum"},{"key":"2026050905165379200_ref20","author":"Elrexfio\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref21","volume-title":"WHO Drug Info","author":"Pozelimabum"},{"key":"2026050905165379200_ref22","author":"Veopoz\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref23","volume-title":"WHO Drug Info","author":"Bimekizumabum"},{"key":"2026050905165379200_ref24","author":"Bimzelx\u00ae Prescribing information","year":"2023"},{"key":"2026050905165379200_ref25","volume-title":"WHO Drug Info","author":"Mirikizumabum"},{"key":"2026050905165379200_ref26","author":"Omvoh\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref27","first-page":"124","volume-title":"WHO Drug Info","author":"Toripalimabum","year":"2019"},{"key":"2026050905165379200_ref28","author":"Loqtorzi\u2122 Prescribing information","year":"2023"},{"key":"2026050905165379200_ref29","first-page":"78","article-title":"Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use","volume":"77","author":"Emmons","year":"1987","journal-title":"Iowa Med"},{"key":"2026050905165379200_ref30","author":"Strohl"},{"key":"2026050905165379200_ref31","volume-title":"Blockbuster biologics 2012, 30"},{"key":"2026050905165379200_ref32","volume-title":"2022 Sales of recombinant therapeutic antibodies, proteins, biosimilars & other biologics, 71"},{"key":"2026050905165379200_ref33","volume-title":"Monoclonal antibodies market size to gain USD 494.44 BN by 2030"},{"key":"2026050905165379200_ref34","volume-title":"2013 Sales of recombinant therapeutic antibodies & proteins.","year":"3\/15\/14."},{"key":"2026050905165379200_ref35","volume-title":"2014 Sales of recombinant therapeutic antibodies & proteins","year":"3\/15\/15"},{"key":"2026050905165379200_ref36","volume-title":"2015 Sales of recombinant therapeutic antibodies & proteins"},{"key":"2026050905165379200_ref37","volume-title":"2016 Sales of recombinant therapeutic antibodies & proteins"},{"key":"2026050905165379200_ref38","volume-title":"2017 Sales of recombinant therapeutic antibodies & proteins"},{"key":"2026050905165379200_ref39","volume-title":"2018 Sales of recombinant therapeutic antibodies & proteins"},{"key":"2026050905165379200_ref40","volume-title":"2019 Sales of recombinant therapeutic antibodies & proteins"},{"key":"2026050905165379200_ref41","volume-title":"2020 Sales of recombinant therapeutic antibodies, proteins, biosimilars & other biologics"},{"key":"2026050905165379200_ref42","volume-title":"2021 Sales of recombinant therapeutic antibodies, proteins, biosimilars & other biologics"},{"key":"2026050905165379200_ref43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/ph16040590","article-title":"Antibody-drug conjugates for multiple myeloma: just the beginning, or the beginning of the end?","volume":"16","author":"Ray","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026050905165379200_ref44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41590-018-0134-y","article-title":"Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota","volume":"19","author":"Tang","year":"2018","journal-title":"Nat Immunol"},{"key":"2026050905165379200_ref45","doi-asserted-by":"crossref","first-page":"1967714","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"MAbs"},{"key":"2026050905165379200_ref46","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","article-title":"Glofitamab CD20-TCB bispecific antibody","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026050905165379200_ref47","first-page":"blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety and resistance mechanisms","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"2026050905165379200_ref48","doi-asserted-by":"crossref","first-page":"20406223211037846","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2026050905165379200_ref49","doi-asserted-by":"crossref","first-page":"1298902","DOI":"10.3389\/fimmu.2023.1298902","article-title":"Case report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis","volume":"14","author":"Luo","year":"2023","journal-title":"Front Immunol"},{"key":"2026050905165379200_ref50","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40265-023-01955-9","article-title":"Pozelimab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"2026050905165379200_ref51","author":"WHO INN Website"},{"key":"2026050905165379200_ref52","doi-asserted-by":"crossref","first-page":"2075078","DOI":"10.1080\/19420862.2022.2075078","article-title":"International nonproprietary names for monoclonal antibodies: an evolving nomenclature system","volume":"14","author":"Guimaraes Koch","year":"2022","journal-title":"MAbs"},{"key":"2026050905165379200_ref53","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J Biol Chem"},{"key":"2026050905165379200_ref54","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026050905165379200_ref55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2026050905165379200_ref56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-B","article-title":"A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody","volume":"30","author":"Angal","year":"1993","journal-title":"Mol Immunol"},{"key":"2026050905165379200_ref57","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/jps.24620","article-title":"Comprehensive analysis of the therapeutic IgG4 antibody pembrolizumab: hinge modification blocks half molecule exchange in vitro and in vivo","volume":"104","author":"Yang","year":"2015","journal-title":"J Pharm Sci"},{"key":"2026050905165379200_ref58","doi-asserted-by":"crossref","first-page":"1779974","DOI":"10.1080\/19420862.2020.1779974","article-title":"Prevention of fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region","volume":"12","author":"Handlogten","year":"2020","journal-title":"MAbs"},{"key":"2026050905165379200_ref59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","article-title":"Optimization of fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"2026050905165379200_ref60","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1074\/jbc.M116.748525","article-title":"Engineering an IgG scaffold lacking effector function with optimized developability","volume":"292","author":"Jacobsen","year":"2017","journal-title":"J Biol Chem"},{"key":"2026050905165379200_ref61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"Vafa","year":"2014","journal-title":"Methods"},{"key":"2026050905165379200_ref62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PloS One"},{"key":"2026050905165379200_ref63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib8030041","article-title":"Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"2026050905165379200_ref64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/cancers11070971","article-title":"Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma","volume":"11","author":"Damato","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026050905165379200_ref65","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"2026050905165379200_ref66","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2023.2236303","article-title":"Elranatamab: a new promising BispAb in multiple myeloma treatment","volume":"23","author":"Grosicki","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026050905165379200_ref67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"2026050905165379200_ref68","author":"Talvey Assessment Report. European Medicines Agency","year":"2023"},{"key":"2026050905165379200_ref69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2026050905165379200_ref70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050905165379200_ref71","first-page":"1126","article-title":"Alzheimer's disease: a molecular view of \u03b2-amyloid induced morbific events","volume":"9","author":"Mohamed Asik","year":"2021","journal-title":"Biomedicine"},{"key":"2026050905165379200_ref72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front Neurosci"},{"key":"2026050905165379200_ref73","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105754","article-title":"Aducanumab for Alzheimer's disease: a regulatory perspective","volume":"171","author":"Nistic\u00f2","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026050905165379200_ref74","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-A\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"2026050905165379200_ref75","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"key":"2026050905165379200_ref76","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/antib4030170","article-title":"Opportunities for conformation-selective antibodies in amyloid-related diseases","volume":"4","author":"Westwood","year":"2015","journal-title":"Antibodies"},{"key":"2026050905165379200_ref77","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMp1701047","article-title":"The failure of solanezumab - how the FDA saved taxpayers billions","volume":"376","author":"Sacks","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050905165379200_ref78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"2026050905165379200_ref79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.48101\/ujms.v128.10316","article-title":"A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease","volume":"128","author":"Lannfelt","year":"2023","journal-title":"Ups J Med Sci"},{"key":"2026050905165379200_ref80","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"2026050905165379200_ref81","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat Neurosci"},{"key":"2026050905165379200_ref82","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2026050905165379200_ref83","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double- blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026050905165379200_ref84","doi-asserted-by":"crossref","first-page":"3946320231209839","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer's disease: a systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2026050905165379200_ref85","doi-asserted-by":"crossref","first-page":"943","DOI":"10.17219\/acem\/171379","article-title":"Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease","volume":"32","author":"Kurkinen","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"2026050905165379200_ref86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The search for CLARITY regarding \"clinically meaningful outcomes\" in Alzheimer disease clinical trials: CLARITY-AD and beyond","volume":"16","author":"Tarawneh","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2026050905165379200_ref87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241091","article-title":"Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model","volume":"16","author":"Cremasco","year":"2021","journal-title":"PloS One"},{"key":"2026050905165379200_ref88","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"2026050905165379200_ref89","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1586\/14737140.8.10.1651","article-title":"Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma","volume":"8","author":"Morrison","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026050905165379200_ref90","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026050905165379200_ref91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imlet.2021.05.006","article-title":"B cells as target for immunotherapy in rheumatic diseases - current status","volume":"236","author":"Bryl","year":"2021","journal-title":"Immunol Lett"},{"key":"2026050905165379200_ref92","volume-title":"WHO Drug Info","author":"Plamotamabum","year":"2019"},{"key":"2026050905165379200_ref93","first-page":"997","volume-title":"WHO Drug Info","author":"Imvotamabum","year":"2021"},{"key":"2026050905165379200_ref94","author":"Lunsumio\u2122 Prescribing information","year":"2022"},{"key":"2026050905165379200_ref95","doi-asserted-by":"crossref","first-page":"20406223231215701","DOI":"10.1177\/20406223231215701","article-title":"Bispecific T cell engagers targeting CD20\/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting","volume":"14","author":"Jin","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"2026050905165379200_ref96","doi-asserted-by":"crossref","first-page":"1168622","DOI":"10.3389\/fonc.2023.1168622","article-title":"T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions","volume":"13","author":"Russler-Germain","year":"2023","journal-title":"Front Oncol"},{"key":"2026050905165379200_ref97","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin's lymphoma: recommended dose safety\/efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"2026050905165379200_ref98","volume-title":"IGM press release: IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting"},{"key":"2026050905165379200_ref99","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2023.2285978","article-title":"Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert","volume":"16","author":"Davis","year":"2023","journal-title":"Rev Hematol"},{"key":"2026050905165379200_ref100","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050905165379200_ref101","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2026050905165379200_ref102","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026050905165379200_ref103","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050905165379200_ref104","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"key":"2026050905165379200_ref105","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"2026050905165379200_ref106","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"2026050905165379200_ref107","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"2026050905165379200_ref108","first-page":"299","article-title":"Immune checkpoint inhibitors win the 2018 Nobel prize","volume":"42","author":"Huang","year":"2019","journal-title":"Biom J"},{"key":"2026050905165379200_ref109","article-title":"Trial watch: immunomodulatory monoclonal antibodies for oncological indications","volume":"4","author":"Buqu\u00e9","year":"2015","journal-title":"Onco Targets Ther"},{"key":"2026050905165379200_ref110","author":"Keytruda\u00ae Prescribing information","year":"2014"},{"key":"2026050905165379200_ref111","author":"Opdivo\u00ae Prescribing information","year":"2014"},{"key":"2026050905165379200_ref112","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2026050905165379200_ref113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.935383","article-title":"POD1UM-303\/InterAACT 2: a phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma","volume":"12","author":"Rao","year":"2022","journal-title":"Front Oncol"},{"key":"2026050905165379200_ref114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2024.0002","article-title":"NCCN guidelines\u00ae insights: Merkel cell carcinoma, version 1.2024","volume":"22","author":"Schmults","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026050905165379200_ref115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/aps.2016.161","article-title":"Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody","volume":"38","author":"Fu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"2026050905165379200_ref116","first-page":"681","article-title":"Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy","volume":"11","author":"Liu","year":"2019","journal-title":"MAbs"},{"key":"2026050905165379200_ref117","doi-asserted-by":"crossref","first-page":"1212813","DOI":"10.3389\/fphar.2023.1212813","article-title":"Anti-PD-1\/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov","volume":"14","author":"Dai","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026050905165379200_ref118","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026050905165379200_ref119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026050905165379200_ref120","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13403","article-title":"Brodalumab: a new way to inhibit IL-17 in psoriasis","volume":"33","author":"Facheris","year":"2020","journal-title":"Dermatol Ther"},{"key":"2026050905165379200_ref121","article-title":"FDA approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric\/adolescents in moderate to severe psoriasis? A systematic review","volume":"12","author":"Aslam","year":"2020","journal-title":"Cureus"},{"key":"2026050905165379200_ref122","first-page":"411","article-title":"The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis","volume":"3","author":"Jenneck","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2026050905165379200_ref123","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14964","article-title":"Physiological roles of human interleukin-17 family","volume":"33","author":"Liu","year":"2024","journal-title":"Exp Dermatol"},{"key":"2026050905165379200_ref124","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.immuni.2008.12.010","article-title":"Interleukin-17A and interleukin-17F: a tale of two cytokines","volume":"30","author":"Dubin","year":"2009","journal-title":"Immunity"},{"key":"2026050905165379200_ref125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"2026050905165379200_ref126","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1038\/s41598-017-08360-9","article-title":"The human IL-17A\/F heterodimer: a two-faced cytokine with unique receptor recognition properties","volume":"7","author":"Goepfert","year":"2017","journal-title":"Sci Rep"},{"key":"2026050905165379200_ref127","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J Immunol"},{"key":"2026050905165379200_ref128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0001-7310(14)70015-8","article-title":"IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease","volume":"105","author":"Mitra","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2026050905165379200_ref129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/jamadermatol.2023.4445","article-title":"The best psoriasis medications emerge","volume":"160","author":"Blauvelt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026050905165379200_ref130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026050905165379200_ref131","author":"Australian Product information, Bimzelx\u00ae Prescribing information","year":"2023"},{"key":"2026050905165379200_ref132","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2026050905165379200_ref133","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035020","article-title":"Pathological mechanism and targeted drugs of ulcerative colitis: a review","volume":"102","author":"Guo","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2026050905165379200_ref134","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"2026050905165379200_ref135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jmb.2008.07.051","article-title":"The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12","volume":"382","author":"Lupardus","year":"2008","journal-title":"J Mol Biol"},{"key":"2026050905165379200_ref136","author":"Ustekinumab\u00ae Prescribing information","year":"2009"},{"key":"2026050905165379200_ref137","author":"Tremfya\u00ae Prescribing information","year":"2017"},{"key":"2026050905165379200_ref138","author":"Ilumya\u00ae Prescribing information","year":"2018"},{"key":"2026050905165379200_ref139","author":"Skyrizi\u00ae Prescribing information","year":"2019"},{"key":"2026050905165379200_ref140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23","volume":"387","author":"Steere","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"2026050905165379200_ref141","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050905165379200_ref142","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13706","article-title":"Risankizumab: mechanism of action, clinical and translational science","volume":"17","author":"Pang","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026050905165379200_ref143","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1111\/bcp.15364","article-title":"Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis","volume":"88","author":"Tran","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026050905165379200_ref144","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"2026050905165379200_ref145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2007.0017","article-title":"Multiple myeloma: most common end-organ damage and management","volume":"5","author":"Hussein","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"2026050905165379200_ref146","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103504","article-title":"Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis","volume":"168","author":"Kiss","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026050905165379200_ref147","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood"},{"key":"2026050905165379200_ref148","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.3390\/ijms21155192","article-title":"B-cell maturation antigen (BCMA) as a target for new drug development in relapsed and\/or refractory multiple myeloma","volume":"21","author":"Abramson","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026050905165379200_ref149","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers15061791","article-title":"The BAFF-APRIL system in cancer","volume":"15","author":"Ullah","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026050905165379200_ref150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11899-022-00682-4","article-title":"The role of belantamab mafodotin, selinexor, and melflufen in multiple myeloma","volume":"17","author":"McCurdy","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"2026050905165379200_ref151","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ejh.14121","article-title":"Teclistamab-cqyv in multiple myeloma","volume":"112","author":"Martino","year":"2023","journal-title":"Eur J Haematol"},{"key":"2026050905165379200_ref152","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/d41573-019-00105-9","article-title":"The BCMA bonanza","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026050905165379200_ref153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026050905165379200_ref154","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026050905165379200_ref155","author":"Darzalex\u00ae Prescribing information","year":"2015"},{"key":"2026050905165379200_ref156","author":"Empliciti\u00ae Prescribing information","year":"2015"},{"key":"2026050905165379200_ref157","author":"Sarclisa\u00ae Prescribing information","year":"2020"},{"key":"2026050905165379200_ref158","author":"Tecvayli\u2122 Prescribing information","year":"2022"},{"key":"2026050905165379200_ref159","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 annual meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026050905165379200_ref160","first-page":"e1220745 (P883)","article-title":"Alnuctamanb (ALNUC; BMS-986349; CC-93269), a BCMA \u00d7 CD3 T-cell engager, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study","volume":"7","author":"Wong","year":"2023","journal-title":"Hema"},{"key":"2026050905165379200_ref161","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"2026050905165379200_ref162","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026050905165379200_ref163","first-page":"501","article-title":"T cell engagement without cytokine storm: a novel BCMA x CD3 antibody killing myeloma cells with minimal cytokine secretion","volume":"130","author":"Buelow","year":"2017","journal-title":"Blood"},{"key":"2026050905165379200_ref164","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"key":"2026050905165379200_ref165","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"2026050905165379200_ref166","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026050905165379200_ref167","author":"Clinicaltrials.gov","year":"2024"},{"key":"2026050905165379200_ref168","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5D x CD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"2026050905165379200_ref169","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.3390\/ijms22115755","article-title":"Fc-receptor targeted therapies for the treatment of myasthenia gravis","volume":"22","author":"Keller","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026050905165379200_ref170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026050905165379200_ref171","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"2026050905165379200_ref172","doi-asserted-by":"crossref","first-page":"1756286420986747","DOI":"10.1177\/1756286420986747","article-title":"VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis","volume":"14","author":"Su","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026050905165379200_ref173","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2026050905165379200_ref174","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"2026050905165379200_ref175","doi-asserted-by":"crossref","first-page":"1756286421997381","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026050905165379200_ref176","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/ijms22063048","article-title":"In translation: FcRn across the therapeutic spectrum","volume":"22","author":"Qi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026050905165379200_ref177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2018.1505464","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"2026050905165379200_ref178","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2023.2296126","article-title":"An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis","volume":"23","author":"Matic","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2026050905165379200_ref179","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026050905165379200_ref180","author":"Vyvgart\u2122 Prescribing information","year":"2021"},{"key":"2026050905165379200_ref181","first-page":"743","volume-title":"Nipocalimabum","year":"2020"},{"key":"2026050905165379200_ref182","first-page":"14","volume-title":"Batoclimabum","year":"2020"},{"key":"2026050905165379200_ref183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2016.12.017","article-title":"Complement in autoimmune diseases","volume":"465","author":"Vignesh","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2026050905165379200_ref184","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41422-023-00779-2","article-title":"Mechanism of activation and biased signaling in complement receptor C5aR1","volume":"33","author":"Feng","year":"2023","journal-title":"Cell Res"},{"key":"2026050905165379200_ref185","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminhematol.2018.02.003","article-title":"Mechanisms of complement-mediated damage in hematological disorders","volume":"55","author":"Taylor","year":"2018","journal-title":"Semin Hematol"},{"key":"2026050905165379200_ref186","author":"Soliris\u00ae Prescribing information","year":"2007"},{"key":"2026050905165379200_ref187","author":"Ultomiris\u00ae Prescribing information","year":"2018"},{"key":"2026050905165379200_ref188","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050905165379200_ref189","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(23)02358-9","article-title":"Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study","volume":"403","author":"Ozen","year":"2024","journal-title":"Lancet"},{"key":"2026050905165379200_ref190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231892","article-title":"Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5","volume":"15","author":"Latuszek","year":"2020","journal-title":"PloS One"},{"key":"2026050905165379200_ref191","doi-asserted-by":"crossref","first-page":"1132740","DOI":"10.3389\/fped.2023.1132740","article-title":"The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: a systematic review and meta-analysis","volume":"11","author":"Turalde-Mapili","year":"2023","journal-title":"Front Pediatr"},{"key":"2026050905165379200_ref192","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1542\/peds.99.3.454","article-title":"Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: respiratory syncytial virus immune globulin study group","volume":"99","author":"Rodriguez","year":"1997","journal-title":"Pediatrics"},{"key":"2026050905165379200_ref193","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003495-199958020-00009","article-title":"Palivizumab","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"2026050905165379200_ref194","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.18749.1","article-title":"The long road to protect infants against severe RSV lower respiratory tract illness","volume":"8","author":"Jares Baglivo","year":"2019","journal-title":"F1000Res"},{"key":"2026050905165379200_ref195","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jac\/dkad076","article-title":"Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants","volume":"78","author":"Jorgensen","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026050905165379200_ref196","doi-asserted-by":"crossref","first-page":"1283120","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front Immunol"},{"key":"2026050905165379200_ref197","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","article-title":"Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants","volume":"29","author":"Wilkins","year":"2023","journal-title":"Nat Med"},{"key":"2026050905165379200_ref198","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050905165379200_ref199","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbae007\/57091246\/tbae007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/7\/2\/132\/57285116\/tbae007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/7\/2\/132\/57285116\/tbae007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:17:17Z","timestamp":1778318237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/7\/2\/132\/7631744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":199,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbae007","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,19]]}}}